The Food and Drug Administration (FDA) has recently approved a new drug, Sotyktu, for the treatment of plaque psoriasis. This marks a significant milestone in the management of this chronic skin condition, which affects millions of people worldwide. In this article, we will delve into the details of this approval, the drug’s mechanism of action, and its potential impact on the lives of those suffering from plaque psoriasis.

FDA Approval of Sotyktu

On September 9, 2021, the FDA announced its approval of Sotyktu (deucravacitinib), a novel oral medication developed by Bristol Myers Squibb, for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. This approval was based on the results of two pivotal Phase 3 clinical trials, POETYK PSO-1 and POETYK PSO-2, which demonstrated the drug’s efficacy and safety in treating plaque psoriasis.

Mechanism of Action

Sotyktu is a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor. It works by blocking the activity of TYK2, a protein involved in the signaling pathways that lead to the overproduction of inflammatory cytokines, which are responsible for the development of plaque psoriasis. By inhibiting TYK2, Sotyktu helps to reduce inflammation and the formation of plaques on the skin.

Clinical Trial Results

The POETYK PSO-1 and POETYK PSO-2 trials enrolled a total of 1,648 adult patients with moderate to severe plaque psoriasis. The primary endpoint of both trials was the proportion of patients achieving a 75% or greater improvement in their Psoriasis Area and Severity Index (PASI 75) score at week 16.

In both trials, Sotyktu demonstrated significant efficacy in achieving PASI 75 at week 16, with 35.7% and 41.1% of patients in POETYK PSO-1 and POETYK PSO-2, respectively, achieving this endpoint. These results were comparable to those observed with the use of Otezla (apremilast), a currently available oral treatment for plaque psoriasis.

Safety and Tolerability

The safety profile of Sotyktu was generally consistent with that of other TYK2 inhibitors. The most common adverse events reported in the clinical trials included upper respiratory tract infections, increased creatine phosphokinase levels, and acne. Serious adverse events were rare, and no new safety signals were identified during the trials.

Potential Impact on Patients

The approval of Sotyktu represents a significant advancement in the treatment of plaque psoriasis. As an oral medication, it offers an alternative to injectable or topical treatments, which may be more convenient for some patients. Additionally, the novel mechanism of action of Sotyktu may provide an effective treatment option for patients who have not responded well to other therapies.

Conclusion

The FDA’s approval of Sotyktu marks a new era in the management of plaque psoriasis. With its unique mechanism of action and promising clinical trial results, this new drug has the potential to improve the lives of millions of people suffering from this chronic skin condition. As further research is conducted, we can expect to gain a deeper understanding of Sotyktu’s role in the treatment of plaque psoriasis and its potential to revolutionize the way we approach this disease.

What do you think about this article? Please share it and comment.

You would like to ask a question, publish an article with us or place and advertisement? Please contact us.